Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Xiaopei Cui"'
Autor:
Shuai Zhang, Yishan Li, Yuanhua Yang, Sugang Gong, Zhenwen Yang, Cheng Hong, Xiaopei Cui, Jun Wan, Yingqun Ji, Hong Chen, Ling Zhu, Chenghong Li, Zhaozhong Cheng, Yunhui Zhang, Qiguang Wang, Qin Luo, Lu Guo, Guofeng Ma, Baoshi Han, Zhihong Liu, Changming Xiong, Lan Wang, Qiushang Ji, Fajiu Li, Shengfeng Wang, Zhu Zhang, Yunxia Zhang, Dingyi Wang, Qian Gao, Qiang Huang, Wanmu Xie, Zhenguo Zhai, Chen Wang
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive pulmonary vascular disorder with substantial morbidity and mortality, also a disease underdiagnosed and undertreated. It is potentially curable by pulmonary en
Externí odkaz:
https://doaj.org/article/026d62af1d194d9d84b39e756824c3a5
Autor:
Chaochao Dai, Hongyu Zhang, Zhijian Zheng, Chun Guang Li, Mingyuan Ma, Haiqing Gao, Qunye Zhang, Fan Jiang, Xiaopei Cui
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionMacrophage-mediated inflammatory response may have crucial roles in the pathogenesis of a variety of human diseases. Growth differentiation factor 15 (GDF15) is a cytokine of the transforming growth factor-β superfamily, with potential a
Externí odkaz:
https://doaj.org/article/293413a69da547e4952f928df7785a7c
Autor:
Jie Wang, Zhijian Zheng, Xiaopei Cui, Chaochao Dai, Jiaxin Li, Qunye Zhang, Mei Cheng, Fan Jiang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
CX-5461, a novel selective RNA polymerase I inhibitor, shows potential anti-inflammatory and immunosuppressive activities. However, the molecular mechanisms underlying the inhibitory effects of CX-5461 on macrophage-mediated inflammation remain to be
Externí odkaz:
https://doaj.org/article/62fbbd220a474034bb5e75d7c1bcf0aa
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
AimSelexipag is an oral selective prostacyclin receptor agonist approved for treatment of patients with pulmonary arterial hypertension (PAH). In the present study, we aim to assess the safety and efficacy of selexipag in triple combination therapy w
Externí odkaz:
https://doaj.org/article/a0343f8bad094ff6b3f3aa16478069d0
Autor:
Guopin Pan, Jing Zhang, Yu Han, Ye Chen, Xiaosun Guo, Xiaopei Cui, Mei Cheng, Haiqing Gao, Jianli Wang, Fan Jiang
Publikováno v:
Pharmacological Research, Vol 177, Iss , Pp 106120- (2022)
CX-5461 is a first-in-class selective RNA polymerase I inhibitor. Previously we found that CX-5461 had anti-inflammatory activities. In this study we characterized potential immunosuppressive effects of CX-5461 and explored the underlying mechanisms.
Externí odkaz:
https://doaj.org/article/2e4eb5730e554b4688de821dd961c102
Autor:
Xiaopei Cui, Huifeng Jia, Hong Xin, Lei Zhang, Shi Chen, Simin Xia, Xue Li, Wei Xu, Xiaofang Chen, Yujie Feng, Xiaoyue Wei, Haijia Yu, Yanting Wang, Yifan Zhan, Xiangyang Zhu, Xuemei Zhang
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Therapeutic monoclonal antibodies (mAbs) blocking immune checkpoints have been mainly used as monotherapy. Recently, combination therapy targeting multiple immune checkpoints has recently been explored to increase anti-cancer efficacy. Particularly,
Externí odkaz:
https://doaj.org/article/a3b267fa67544fc5a32b0e5de324c6a1
Autor:
Jin Zhang, Yangyang He, Xiaosong Yan, Shanshan Chen, Ming He, Yuyang Lei, Jiao Zhang, Brendan Gongol, Mingxia Gu, Yifei Miao, Liang Bai, Xiaopei Cui, Xiaojian Wang, Yixin Zhang, Fenling Fan, Zhao Li, Yuan Shen, Chih‐Hung Chou, Hsien‐Da Huang, Atul Malhotra, Marlene Rabinovitch, Zhi‐Cheng Jing, John Y‐J Shyy
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 5, Pp n/a-n/a (2020)
Abstract Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit. Lower levels of miR‐483 were found in serum from patients
Externí odkaz:
https://doaj.org/article/9fca316f951a47569ae67456c7e5de14
Publikováno v:
Emergency & Critical Care Medicine; Jun2024, Vol. 4 Issue 2, p60-66, 7p
Autor:
Chaochao Dai, Hongyu Zhang, Zhijian Zheng, Chun Guang Li, Mingyuan Ma, Haiqing Gao, Qunye Zhang, Fan Jiang, Xiaopei Cui
Publikováno v:
Frontiers in Immunology; 2024, p1-17, 17p
Autor:
Xiaopei Cui, Xi Zhu, Haijia Yu, Jingen Xu, Xiaoyue Wei, Shi Chen, Yangtin Wang, Xiaofang Chen, Yujie Feng, Xiaochen Ren, Liyang Fei, Bin Xie, Mingwei Li, Xue Li, Huifeng Jia, Simin Xie, Li Chen, Yong Cheng, Lei Zhang, Haidong Li, Xiangyang Zhu, Yifan Zhan
Co-targeting PD-1/PD-L1 and TIGIT/CD226 is being pursued to broaden the efficacy of current immunotherapy. Here we demonstrate that a bispecific antibody (BsAb) targeting PD-L1 and TIGIT, HB0036, shows major advantages over the combination of the two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa4b517a26989fbd8310939cc91c4003
https://doi.org/10.1101/2023.05.11.540461
https://doi.org/10.1101/2023.05.11.540461